○Yutaka Oji1, Taku Hatano1, Shin-ichi Ueno1, Manabu Funayama2, Kei-ichi Ishikawa1,3, Ayami Okuzumi1, Shigeto Sato1, Wataru Satake4, Tatsushi Toda4, Yuanzhe Li1, Taiji Tsunemi1, Kenya Nishioka1, Tatsuro Mutoh5, Yoshihisa Takiyama6, Masahito Yamada7, Matthew Farrer8,9, Yasuo Uchiyama2, Wado Akamatsu3, Junko Matsuda4,10, Nobutaka Hattori1,4 (1.Department of Neurology, Juntendo University School of Medicine, Japan, 2.Research Institute for Diseases of Old Age, Graduate School of Medicine, Juntendo University, 3.Center for Genomic and Regenerative Medicine, Juntendo University, 4.Department of Neurology, University of Tokyo, 5.Department of Neurology, Fujita Health University, 6.Department of Neurology, University of Yamanashi, 7.Department of Neurology, Kanazawa University, 8.Department of Neurology, University of Florida, 9.Department of Medical Genetics, University of British Columbia, 10.Department of Pathophysiology and Metabolism, Kawasaki Medical School)
Session information
[held on paper]Oral Session
[O-24] Oral Session 24
Neuroscience 1 E
[O-24-2] Aberrant cytoplasmic aggregation of TDP-43 is prevented by interaction with G3BP1 and USP10
○Masahiro Fujii1, Masahiko Takahashi1, Hiroki Kitaura2, Akiyoshi Kakita2, Taichi Kakihana1, Yoshinori Katsuragi1, Yuriko Iwakura3, Hiroyuki Nawa3, Akihide Koyama4, Osamu Onodera4 (1.Division of Virology, Niigata Graduate School of Medical and Dental Sciences, Japan, 2.Department of Pathology, Brain Research Institute, University of Niigata, 3.Department of Molecular Neurobiology, Brain Research Institute, University of Niigata, 4.Department of Neurology, Brain Research Institute, University of Niigata)
○Kazuhiko Watabe1,2, Yoichiro Kato2, Miho Sakuma3, Makiko Murata1, Motoko Niida2, Taro Takemura4, Nobutaka Hanagata4, Mari Tada5, Akiyoshi Kakita5, Noriyuki Shibata2 (1.Department of Medical Technology (Neuropathology), Faculty of Health Sciences, Kyorin University, Japan, 2.Department of Pathology, Division of Pathological Neuroscience, Tokyo Woman's Medical University, Japan, 3.School of Medicine, Tokyo Woman's Medical University, 4.Research Network and Facility Services Division, National Institute for Materials Science, 5.Department of Pathology, Brain Research Institute, Niigata University)
○Yukio Takeshita1, Susumu Fujikawa1, Tomotaka Okino2, Miwako Fujisawa1, Fumitaka Shimizu1, Toshihiko Maeda1, Yasuteru Sano1, Michiaki Koga1, Takashi Kanda1 (1.Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Japan, 2.Ono Pharmaceutical co., LTD)
○Yutaka Ohsawa1, Yoshihide Sunada1, Shunichi Shirakawa1, Hiroki Hagiwara2 (1.Neurology, Kawasaki Medical School, Japan, 2.Medical Science, Teikyo University of Science)
○Eiichiro Mori1, Hitoki Nanaura2, Tomo Shiota2, Kazuma Sugie2 (1.Department of Future Basic Medicine, Nara Medical University, Japan, 2.Department of Neurology, Nara Medical University)
○Rie Tohge, Satoshi Kaneko, Satoshi Morise, Mitsuaki Oki, Masataka Nakamura, Norihiro Takenouchi, Hirofumi Kusaka (Department of Neurology, Kansai medical university, Japan)
○Weidong Le (The First Affiliated Hospital, Dalian Medical University, China)
○Tatsufumi Murakami1, Shigenobu Toné2, Kazunori Sango3, Mineykuki Mizuguchi4, Kazuhiko Watabe5, Yoshihide Sunada1 (1.Department of Neurology, Kawasaki Medical School, Japan, 2.Graduate School of Science and Engineering, Tokyo Denki University, 3.Department of Sensory and Motor Systems, Tokyo Metropolitan Institute of Medical Science, 4.Faculty of Pharmaceutical Sciences, University of Toyama, 5.Faculty of Health Sciences, Kyorin University)